Safety remains the key metric for Cogent
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
Licensing analysis: big deals bolster biotech
PD-(L)1 x VEGF bispecifics prove a big draw.
When two antigens are better than one
Multispecifics newly into the clinic include Car-Ts from Essen and Unicar.
Conjugates dominate human trial entries
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
Dizal's US first; now what?
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Regeneron enters the T-cell engager arena
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
M&A analysis: signs of life emerge
Some big deals in the second quarter have raised hopes that takeouts are back.
